BioPorto A/S (CPH:BIOPOR)
Denmark · Delayed Price · Currency is DKK 1.012
-0.002 (-0.20%)
Jan 23, 2026, 2:04 PM CET
BioPorto Revenue
BioPorto had revenue of 10.41M DKK in the quarter ending September 30, 2025, with 7.44% growth. This brings the company's revenue in the last twelve months to 36.56M, up 4.74% year-over-year. In the year 2024, BioPorto had annual revenue of 36.24M with 17.07% growth.
Revenue (ttm)
36.56M
Revenue Growth
+4.74%
P/S Ratio
13.73
Revenue / Employee
761.69K
Employees
48
Market Cap
502.03M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36.24M | 5.29M | 17.07% |
| Dec 31, 2023 | 30.96M | 1.99M | 6.87% |
| Dec 31, 2022 | 28.97M | 4.72M | 19.44% |
| Dec 31, 2021 | 24.25M | 1.05M | 4.53% |
| Dec 31, 2020 | 23.20M | -3.42M | -12.84% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 315.60B |
| Coloplast | 27.87B |
| Genmab | 24.48B |
| ALK-Abelló | 6.08B |
| Gubra | 2.64B |
| ChemoMetec | 495.57M |
| Scandinavian Medical Solutions | 245.44M |
| ViroGates | 8.11M |
BioPorto News
- 2 months ago - BioPorto A/S raises approximately DKK 43 million in new capital round - Change in number of shares and votes - GlobeNewsWire
- 2 months ago - BioPorto A/S 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 2 months ago - Private placement of 40,438,426 new shares fully subscribed – gross proceeds of approximately DKK 43 million to BioPorto A/S - GlobeNewsWire
- 2 months ago - BioPorto Executes on its Financing Strategy- BioPorto A/S initiates pre-subscribed private placement - GlobeNewsWire
- 2 months ago - Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025 - GlobeNewsWire
- 4 months ago - BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented - GlobeNewsWire
- 5 months ago - BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth. - GlobeNewsWire
- 5 months ago - BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth. - Benzinga